AVS Bio
Private Company
Total funding raised: $10.5M
Overview
AVS Bio operates at the intersection of biologics manufacturing and drug discovery services, with a core foundation in Specific Pathogen-Free (SPF) eggs and avian biologicals. It has expanded into a full-service provider offering custom antibody and protein engineering, preclinical testing via its UK-based CRO RoukenBio, and support for clinical-stage programs. The company serves a diverse market from global biopharma to animal health, boasting a substantial production history and a portfolio that supports products from research through clinical trials.
Technology Platform
Integrated platform centered on USDA-licensed avian biological manufacturing (SPF eggs, antigens) combined with antibody/protein engineering and a specialized immunology CRO (RoukenBio) for preclinical immune cell assay testing.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Competes with large life science tools suppliers (e.g., Thermo Fisher, Merck KGaA) for materials and with global CROs (e.g., Charles River, Labcorp) for discovery services. Differentiation lies in its specialized avian platform, integrated offering, and niche immunology expertise through RoukenBio.